Paris

• A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting
  2025-522012-16-00 4 2026-03-13 Breast Cancer
• Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting
  2025-521416-19-00 4 2026-03-12 Recurrence of Clostridioides difficile Infection
• Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-522713-29-00 5 2026-03-12 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with sele … Recruiting
  2024-519788-16-00 4 2026-03-05 Adult patients with histologically/cytologically confirmed progressive
• Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com … Recruiting
  2025-521284-12-00 5 2026-03-05 Non-small cell lung cancer
• BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting
  2024-520128-27-00 4 2026-03-04 colorectal adenocarcinoma
• A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma Recruiting
  2025-521785-10-00 5 2026-03-04 Glioblastoma
• RUBIKID - Dynamic 82-Rb positron emission tomography (PET) for the grading of KIDney carcinoma Recruiting
  2024-514085-39-00 4 2026-03-03 Kidney carcinoma
• Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combin … Recruiting
  2023-506291-28-00 5 2026-03-02 Patient with locally advanced/metastatic, MSI-H/dMMR gastric cancer
• A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard … Recruiting
  2025-521634-29-00 5 2026-03-02 Acute Myeloid Leukemia
• A Safety and Efficacy Study of GTX-102 in Subjects with Deletion- or Nondeletion-type Angelman Syndrome (Aurora) Recruiting
  2024-519393-39-00 4 2026-02-27 Angelman Syndrome
• Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs Recruiting
  2025-523297-16-00 1 2026-02-27 Non-Hodgkin Lymphoid Malignancies (NHLs)
• Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting
  2025-522015-42-00 10 2026-02-26 Chronic Hepatitis D Infection
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transpl … Recruiting
  2025-521257-17-00 7 2026-02-25 SCD severe patients
• INFINITY - Effect of interferon gamma as a treatment for post-aggressive immunosuppression in intensive care units, a randomized Bayesian do … Recruiting
  2023-506725-11-00 5 2026-02-24 Post-aggressive immunosuppression
• PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai … Recruiting
  2025-522108-26-00 4 2026-02-19 métastatique colorectal cancer
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line … Recruiting
  2024-517766-41-00 4 2026-02-17 Patients with metastatic pancreatic ductal adenocarcinoma.
• Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease ( ATTAIN-PAD ) Recruiting
  2025-523283-21-00 5 2026-02-17 Peripheral Arterial Disease
• Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine Recruiting
  2024-518190-34-00 6 2026-02-16 rheumatic disease
• A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon … Recruiting
  2025-521880-10-00 9 2026-02-16 Metastatic castrate resistant prostate cancer (mCRPC)

Showing 529–552 of 2,322 trials